BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Immunocore, GlaxoSmithKline deal

Immunocore partnered with GlaxoSmithKline to use Immunocore's ImmTAC technology to discover and develop ImmTACs against multiple undisclosed targets selected by GSK for cancer and infectious disease indications. ImmTACs are bi-specific molecules consisting of a soluble monoclonal T cell receptor (mTCR) fused to an...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >